Cristal Therapeutics is a clinical stage pharmaceutical company developing the next generation of nanomedicines based on its proprietary CriPec® platform to treat various diseases, including cancer. CriPec is perfectly suited for the development of highly customizable (targeted) nanomedicines with superior efficacy and safety profiles. The most advanced product in development is CriPec docetaxel for the treatment of solid tumours.
